Kisspeptin-10
Kisspeptin-10 (Metastin 45-54)
Also known as: KP-10, Metastin fragment, Kisspeptin decapeptide
Prompted by Jack Butcher (Visualize Value) · AI-authored by Claude · Research-sourced
The master upstream regulator of reproductive hormones — signals the hypothalamus to release GnRH. Brain imaging shows it also enhances sexual arousal through limbic circuits independent of hormonal effects.
Quick Facts
Not FDA-approved. Currently in clinical trials for reproductive medicine and sexual health applications.
Overview
Kisspeptin-10 is a 10-amino-acid fragment of the 54-amino-acid neuropeptide kisspeptin (metastin). Kisspeptins are the endogenous ligands of the GPR54 receptor (KISS1R) and are the master regulators of the hypothalamic-pituitary-gonadal (HPG) axis.
Kisspeptin signaling is essential for puberty onset, reproductive hormone release, and fertility. It acts upstream of GnRH (gonadotropin-releasing hormone) — it is the signal that tells the hypothalamus to release GnRH, which then triggers LH and FSH release from the pituitary.
Recent research has revealed kisspeptin also plays a role in sexual arousal and attraction behavior, independent of its reproductive hormone effects. Brain imaging studies show kisspeptin enhances activity in brain regions associated with sexual processing and romantic attraction.
Mechanism of Action
Kisspeptin-10 activates the KISS1R receptor (GPR54) on GnRH neurons in the hypothalamus. This triggers GnRH release into the hypophyseal portal system, which stimulates the anterior pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
LH and FSH then act on the gonads to stimulate testosterone production (in males) and estrogen/progesterone production plus ovulation (in females). This makes kisspeptin a physiological "upstream switch" for the entire reproductive hormone cascade.
Brain imaging research using fMRI shows kisspeptin administration enhances activity in the medial preoptic area, anterior cingulate cortex, and other limbic structures associated with sexual arousal, emotional bonding, and reward processing — independent of its hormonal effects.
Research Summary
Clinical trials at Imperial College London and other centers have demonstrated kisspeptin's effects on both reproductive hormones and sexual behavior in humans.
In healthy men, intravenous kisspeptin-54 infusion increased LH levels by 3-fold and testosterone by 1.5-fold. Kisspeptin-10, the shorter fragment, produces similar but more transient effects due to its shorter half-life.
fMRI studies by Dhillo et al. showed kisspeptin enhanced brain activity in sexual processing regions when viewing attractive faces and sexual images. Participants reported enhanced sexual arousal and more positive mood during kisspeptin infusion.
In women with hypothalamic amenorrhea (absent periods due to stress/low weight), kisspeptin infusion restored LH pulsatility, suggesting therapeutic potential for functional hypothalamic disorders.
Kisspeptin differs from PT-141 in mechanism: PT-141 acts on melanocortin receptors in the brain, while kisspeptin acts on GnRH neurons and limbic circuits. They target different pathways to influence sexual function.
Key References
Kisspeptin enhances brain responses to olfactory and visual cues of attraction in men
Comninos AN, et al. · JCI Insight (2017) · 10.1172/jci.insight.93999
fMRI study showing kisspeptin enhances brain activity in sexual and emotional processing regions in healthy men, independent of hormonal changes.
Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization
Abbara A, et al. · Journal of Clinical Investigation (2015) · 10.1172/JCI75730
Clinical trial using kisspeptin as a safer alternative to hCG trigger for oocyte maturation in IVF, with reduced risk of ovarian hyperstimulation syndrome.
Kisspeptin stimulates LH secretion in humans with a mechanism distinct from GnRH
Dhillo WS, et al. · Journal of Clinical Endocrinology & Metabolism (2005) · 10.1210/jc.2005-1468
First demonstration in humans that kisspeptin stimulates LH and FSH release, confirming its role as the upstream regulator of the HPG axis.
Protocols
Research / clinical setting
Clinical trials use IV infusion for precise dosing. Due to the very short half-life (~4 minutes for KP-10), IV is preferred over subcutaneous injection in research settings.
Subcutaneous (exploratory)
Subcutaneous use is less studied. The short half-life means effects are transient. Kisspeptin-54 has a longer half-life than kisspeptin-10 and may be preferred for subcutaneous use.
Side Effects & Safety
| Frequency | Effect |
|---|---|
| common | Flushing Warmth and facial flushing shortly after administration. Transient. |
| uncommon | Elevated heart rate Mild, transient tachycardia reported in some studies. |
| uncommon | Headache |
| rare | Abdominal discomfort |
Contraindications
- —Hormone-sensitive cancers (kisspeptin elevates sex hormones)
- —Pregnancy (disruption of normal reproductive hormone signaling)
- —Pituitary disorders
Reconstitution & Storage
Related Peptides
Kisspeptin and PT-141 act through entirely different mechanisms — kisspeptin on GnRH/limbic circuits, PT-141 on melanocortin receptors. They represent complementary approaches to sexual health but have not been studied in combination.